With this acquisition, Olon said it has successfully finalized its three-year development plan and will now move to its next target, which is to play an important role in manufacturing biologics APIs.
Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
Newsletter & e-edition
News, trends and background information as well as the latest issue of CHEManager International